RPG Life Sciences Ltd
RPG Life Sciences Q1 FY26: Capex ₹140 Cr
Q1 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on RPG Life Sciences Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1 FY26 Revenue from Operations: Rs. EBITDA: ₹40.7 crore in Q1 FY26 vs ₹41.4 crore in Q1 FY25, a decline of 1.7%.
From RPG Life Sciences Ltd's Q1 FY26 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q1 FY26 Revenue from Operations: Rs. 168.9 crores vs Rs. 165.4 crores in Q1 FY25 (+2.1% YoY).
- EBITDA: Rs. 40.7 crores in Q1 FY26 vs Rs. 41.4 crores in Q1 FY25 (‐1.8% YoY).
- PBT: Rs. 35.4 crores in Q1 FY26 vs Rs. 36.0 crores in Q1 FY25 (‐1.6% YoY).
- PAT: Rs. 26.3 crores in Q1 FY26 vs Rs. 26.8 crores in Q1 FY25 (‐1.8% YoY).
- Domestic Formulations: Rs. 115.5 crores in Q1 FY26, +9.5% YoY.
- API segment: Rs. 19.6 crores in Q1 FY26, ‐22.4% YoY, impacted by a fire incident.
2 more points management made on revenue & sales performance
Profitability & Margins
See what RPG Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Since FY22, RPG Life Sciences infused ₹140 crores capex to build a modern plant, approved by EU, TGA, PMDA, etc. (Page 27)
- Modernization and capacity expansion are underway at multiple manufacturing units including Formulations Units 1 & 2 (Ankleshwar) and API Unit (Navi Mumbai) (Page 23)
- The state-of-the-art, EU/TGA approved plant with enhanced capacity supports global business build-up, linked with the ₹140 crores capex infusion (Pages 21, 27)
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what RPG Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
RPG Life Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹177 Cr, net profit ₹30 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What RPG Life Sciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharmaceuticals Ltd (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories Ltd (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem Ltd (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- Influx Healthtech Ltd (Q1 FY26)
FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26). Key concall takeaways from Influx Healthtech Ltd's Q1 FY26…
Frequently Asked Questions
What were RPG Life Sciences Ltd Q1 FY26 results?
Q1 FY26 Revenue from Operations: Rs. EBITDA: ₹40.7 crore in Q1 FY26 vs ₹41.4 crore in Q1 FY25, a decline of 1.7%.
What is RPG Life Sciences Ltd share price analysis?
RPG Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 39.7 with a market cap of ₹4,635 Cr. Investors should review the full earnings analysis for detailed insights.
Is RPG Life Sciences Ltd planning capital expenditure?
Since FY22, RPG Life Sciences infused ₹140 crores capex to build a modern plant, approved by EU, TGA, PMDA, etc.
Keep RPG Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.